Nuvation Bio Inc. cotiza a 4.90 USD y tiene una capitalización bursátil de $1.7B. En los últimos 12 meses ha facturado $170M con un margen de flujo de caja libre del -288.4%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhib…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-0.15 | $0.01 | $-0.09 |
| Estimado | $-0.09 | $-0.12 | — | $-0.04 |
| Sorpresa | — | -25.0% | — | -125.0% |
| Métrica | NUVB | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -338.7% | -38.6% | -300.1% |
| Net Margin | -325.3% | -33.6% | -291.8% |
| FCF Margin | -288.4% | -13.9% | -274.6% |
| ROE | -66.9% | -40.4% | -26.5% |
| ROA | -34.4% | -32.0% | -2.4% |
| Current Ratio | 6.95 | 2.84 | +4.11 |
| Debt / Equity | 0.15 | 0.28 | -0.13 |